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Abstract
The Opioid Crisis has claimed the lives of over 1 million Americans since the 1990’s.
Rates of fatal opioid overdoses have risen dramatically due to the corrupted nature of Purdue
Pharma and the increased prevalence of highly potent synthesized opioids. In the United States,
nearly 2.5million individuals need treatment while only a fraction of them are able to receive
treatment. Unfortunately, due to high dropout rates, the effectiveness of current Opioid Use
Disorder treatment cannot be properly evaluated. Since the Covid-19 pandemic, states have been
tackling the Opioid Crisis by implementing treatment initiation and retention strategies. These
strategies aim at targeting at-risk populations and providing them with long-term patient-oriented
treatment, along with implementing a harm reduction philosophy to current treatment protocols.
The implementation of these public health strategies have the possibility to dramatically decrease
the current treatment gap and improve the effectiveness of current Opioid Use Disorder
treatment. This is a major step forward in combating the crisis.
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I.Introduction
The Opioid Epidemic: Where it Started and Where We Are Now

The introduction of prescription opioids in the United States Health Care system led to
opioid-related deaths to become the 4th leading cause of death in the United States. Since the
late 1990’s, there has been a rise in opioid misuse throughout the United States due to the
corrupted nature of big Pharmaceutical companies. From 1990 to 1995, there was a drastic
increase in opioid prescriptions due to the FDA approval of Oxycontin. This long-acting opioid,
Oxycodone, was promoted as a non-addicting drug and was quickly administered to patients in
order to control and treat their pain. There was some effort in order to implement risk
management programs to accompany the increased distribution of opioids, but the efforts did not
adequately manage the misuse/abuse of opioids (Bernard et al., 2018). It wasn’t until 2017,
almost two decades later, that the rise in opioid abuse and deaths was considered a public health
crisis.

Ii. History of Opiates
Opioids have been used historically for various medical purposes but were first widely
used in the United States during the Civil War to treat wounded soldiers. Morphine was the main
opioid used in order to manage the pain that soldiers presented. Unfortunately, many of these
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soldiers developed an addiction. Heroin was later introduced in the 1890’s into the medical
setting and since it was synthetically made from morphine, individuals believed that it was less
habit-forming, which was quickly disproven by the increased rates of heroin abuse (Bernard et
al., 2018).
Later, opioids were primarily used to treat pain in cancer patients. In the 1990’s, opioids
such as Oxycontin were first administered and prescribed to patients with acute or chronic pain.
During this time, many medical practitioners believed that opioids shouldn’t be administered in a
clinical setting due to the increased risk of misuse in patients with chronic pain. The tactics of
persuasion used by Purdue Pharma’s marketing team led to many medical practitioners
prescribing Oxycodone despite their hesitations. Medical practitioners along with many others,
knew that individuals with chronic pain often dealt with mental health issues, which could
increase their risk of developing a dependency if the medication was not assisted by behavioral
and/or psychological therapy.
During the same period, the American Pain Society heavily marketed oxycodone and
other narcotics in order to treat pain. Purdue Pharma primarily funded American Pain Society in
order to increase their revenue. Within the first couple years, both prescription rates for
Oxycodone increased along with ER visits due to opioid-related complications and overdoses
(Hirsch, 2017). From historical observations, opioids are highly addictive drugs that need to be
paired with proper surveillance and pain management therapy.
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Iii. The Different Types of Opioids and Their Prevalence
As previously stated, there are many types of Opioids. Opioids are derived from the
opium plant and can either be natural, semi-synthetic, or fully synthetic. Natural opiates such as
morphine can be transformed into codeine through man-made chemical processes. These natural
opiates are mainly used in order to treat pain, often in a hospital setting. Secondly,
semi-synthetic opioids such as: oxycodone, hydrocodone, hydromorphone, and oxymorphone
are mainly prescribed to individuals with acute/ chronic pain. Lastly, there are synthetically made
opioids such as Tramadol, Fentanyl, and Heroin, which are extremely potent compared to natural
and semi-synthetic opioids. Opioids that are not regulated and distributed through illegal means
bring about an increased risk of contamination with more potent opioids that increase the risk of
fatal overdoses.
Opioids are currently primarily used in a medical setting to block pain signals in order to
treat pain. Opioids also bring about other effects such as: sedation, euphoria, relaxation… The
positive effects of opioids are the reason behind the increased misuse and abuse (Hirsch, 2017).
Individuals who had become addicted to oxycodone during the first wave of the opioid crisis,
soon turned to heroin due to its increased accessibility and potency. Heroin usage skyrocketed
due to prescription opioid misuse, in which 80% of active heroin users previously abused
oxycodone and other prescription pain medication. Without proper surveillance and other modes
of pain management individuals have a heightened risk of becoming addicted and turning to
other drugs that increase one’s risk of overdosing.
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Iiia. Prevalence of Fentanyl and other Synthetic Opioids
We are currently living through the third wave of the opioid epidemic, in which fentanyl
is the driving force behind the increased rates of fatal overdoses. In the past decade, there has
been a drastic increase in the number of cases of overdoses relating to Fentanyl. Fentanyl is
mainly used as an anesthetic within a medical setting because of its potency and effects.
Compared to morphine, fentanyl is 100% more potent (Fentanyl, n.d.). From 2011 to 2018,
according to the CDC, the rate of fatal overdoses caused by fentanyl dramatically increased. This
was primarily linked to the fact that many drugs on the market were cut with fentanyl. Since
fentanyl has a high potency, it doesn’t take that much of the substance to produce a high which
led many other drugs to be laced with it. Furthermore, fentanyl was also prescribed in order to
treat chronic pain patients when oxycodone no longer worked due to tolerance. (4 Strategies for
Combating the Third Wave of the Opioid Epidemic, n.d.).

Iiii. The Role of Purdue Pharma
Purdue Pharma invested heavily in promoting their drug, Oxycontin. They received a
special FDA approval label that stated it was a non-addictive substance even though historically
opioids always pose an increased risk for misuse and abuse. Sales reps were trained to persuade
physicians to prescribe Oxycontin to their patients with severe/chronic pain. They additionally,
used databases in order to track physicians who had high rates of patients with chronic pain.
Sales reps were first ordered to go to rural areas in West Virginia, Kentucky, New Hampshire,
Pennsylvania, and Ohio, where rates of chronic pain were high. In these rural areas, there were
high rates of work injury due to manual labor being the main source of income. In these
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communities where oxycontin was first introduced, the rate of abuse increased dramatically
(Van Zee, 2009) .
Furthermore, Purdue Pharma advertised Oxycontin as a breakthrough drug that could
cure pain. The techniques and forms of persuasion led many doctors to prescribe Oxycontin to
their patients. From 1996 to 2001, more than 40 national pain-management conferences were
held. Doctors, nurses, and pharmacists from around the country were invited to these heavily
funded campaigns. From 1996 to 2000, sales grew from $48 million to around $1.1 billion. (Van
Zee, 2009) By 2004, Oxycontin became the most misused prescription opioid in the US.
(Oxycodone: How Did We Get Here and How Do We Fix It? - BPJ 62 July 2014, n.d.).
Additionally, the opioid epidemic came in three different waves. First, in the 1990's the
implementation of opioids in a medical setting correlated with a rise in overdose deaths. As
prescription opioids became harder to find/purchase, rates of heroin usage went up. Later, in
2013, synthetic opioids were readily available and were often illicitly manufactured. In the third
decade of the Opioid Epidemic, the increased prevalence of Fentanyl is the leading cause of
opioid related overdoses. The forms of persuasion and unethical practices on the part of Purdue
Pharma is the reason why there is an opioid crisis and that opioid -related deaths reached a
record high in 2021, in which 100,000 individuals died (Understanding the Epidemic | CDC’s
Response to the Opioid Overdose Epidemic | CDC, 2021).

Over the past three decades, the United States has seen a stark rise in fatalities linked to
the overprescription of opioids, along with the usage of heroin and other synthetically made
opioids. As doctors across the US prescribed oxycodone and other pain killers, patients quickly
developed a dependency on them. Cases of Opioid Use Disorders increased, leaving millions of
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individuals to continue using prescription opioids and later using heroin as a cheaper means of
getting high. Opioid Use Disorders (OUD) are very complex disorders that cannot be fixed
without proper treatment due to the underlying neurobiological and physical changes that are
present in chronic users. Opioid Use Disorders are linked to a drastic decrease in quality of life,
social relations, job performance, and increased illegal behavior. Additionally, OUD does not
discriminate based on age, sex, and/or race. There are of course certain risk factors that increase
one’s risk, though anyone who has been prescribed oxycodone is at risk of developing an
addiction due to its highly reinforcing properties.

II. Diagnosis of Opioid Use Disorder

As previously mentioned, Opioid Use Disorders stem from the misuse and abuse of
opioids. Opioid use disorders are one of the most challenging mental health disorders to treat.
In the United States alone, over 2 million individuals are diagnosed with OUD each year. Within
this population, 120,000 deaths occur due to opioid-related overdoses. The misuse and abuse of
opioids is linked to physiological and behavioral dependencies of the drug (Hirsch, 2017). 1
Opioid Use Disorder is characterized by chronic misuse/ abuse of opioids with the
presence of withdrawal symptoms. During the first wave of the opioid epidemic, opioids were
primarily ingested orally. During the second and third wave of the opioid epidemic, opioids
were often intravenously injected or administered intranasally (e.g. heroin and fentanyl). As the
rates of prescribing Oxycontin increased, more and more individuals began abusing the drug.
The long-acting Oxyconton was promoted as a non-addictive drug because of the delayed onset

1

For the diagnosis criteria see appendix p.60
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and duration of the effects. Oxycontin was said to be slowly released into the body over a period
of 12hrs in order to reduce one’s pain throughout the day. Though as individuals' tolerances
grew, there was a diminished effect of the drug. Soon individuals started to crush and snort
Oxycontin in order for the onset of the effects to take place faster. Depending on the different
routes of administration, the onset, duration, and effects of the drugs differ along with the
increased risk of physical and psychological dependencies (Kosten & George, 2002).

When an individual repeatedly takes a narcotic, they develop a tolerance. Meaning, that
in order for the effects of the opioids to occur one has to increase the dosage. When one develops
a tolerance, withdrawal symptoms will most likely occur. As the body and brain adapt to
repeated drug usage, it becomes dependent on the presence of said drug. Meaning that, repeated
exposure to escalating doses of opioids alters the brain so that it functions more or less normally
when the drugs are present and abnormally when they are not. Withdrawal symptoms are often
not deadly but pose a major physical and psychological toll on the individual (Opiate and Opioid
Withdrawal, 2021).

IIi. Prevalence of Opioid Use Disorders in the United States

In the United States, we have seen a rise in Opioid Use Disorders since the 1990s. As
different opioids became more available, so did the prevalence of increased opioid abuse. In
2017, around 1.7 million people in the United States suffered from prescription pain reliever
substance abuse disorders. Additionally, nearly 600,000 people in the United States suffer from
heroin use disorder. The rise in synthetic opioid usage has been correlated to a stark rise in
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fatalities. Moreover, a demographic study analyzed the rise in overdose deaths among
individuals dependent on race (see figure 1). Understanding the trends is important to better
assessing which populations have been most affected by the current opioid epidemic.

( Fig 1) The figure above shows the rate of overdose deaths based on race. The highest rates of overdose
deaths during that past 18 years are present among Native Americans and white individuals. From 2013
to 2018, there has been a 120 percent increase in overdose rates among Black American (9.58 and 21.04
per 100,000 from 2013 to 2018) (Overdose Deaths and Jail Incarceration - National Trends and Racial…,
n.d.).

Understanding the scope of the Opioid Epidemic and the various trends seen throughout
it is important in creating equitable public policy changes. America’s War on Drugs has
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perpetuated the discriminatory practices seen within the Criminal Justice System. Moreover,
even within the healthcare setting there is still stigma surrounding substance abuse disorders,
which further perpetuates the continued cycle of opioid abuse. Understanding the scope of the
epidemic is crucial in understanding which populations are most at risk in order to create public
health policies that not only target at-risk populations but ensure that more treatment becomes
accessible.

IIiii. Populations at Higher Risk

IIiiia. Individuals with Chronic Pain
Opioid Use Disorders don’t discriminate based on gender, race, and/or age, though there
are some risk factors that increase one’s risk of developing an addiction. Major pharmaceutical
companies like Purdue Pharma first targeted at- risk populations because of their ability to
increase profit. Within these populations, there was often no associated care given in order to
observe the patient's medical and psychological needs. Chronic pain, psychological distress,
financial burdens, poor social/familial support, and many other factors are not accounted for
when individuals are prescribed narcotics such as Oxycodone.
Individuals who suffer from chronic pain are at a higher risk of developing an addiction.
A systematic review conducted by Vowels et al., 2015 found that between 21%-29% of patients
with chronic pain that were treated with opioids misused them. Furthermore, from that 21% to
29%, on average 8-12% of patients developed an addiction. Individuals with chronic pain often
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present with comorbid physical and psychiatric disorders, which accounts for the heightened risk
of developing an addiction (Vowles et al., 2015).

IIiiib. Newly Released Incarcerated Individuals
Moreover, individuals who are released from prison are at a much higher risk of
overdosing due to past substance abuse disorders and lowered tolerances. Due to the lack of
treatment for individuals within this criminal justice system and stigma surrounding addiction,
rates of preventable fatal overdoses are heightened once inmates are released (fig.2).
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Organizations that have been tracking the Opioid Epidemic and its various trends have
addressed the issues present within the criminal justice system. The Substance Abuse and Mental
Health Services Administration (SAMHSA) is a branch of the U.S Department of Health and
Human Services. This organization has been tracking various trends relating to substance abuse
and mental health disorders in order to integrate data into public policy making. A report by
SAMHSA found that individuals who are recently released from prison and who have had a
history of opioid abuse are 10 to 40 times more likely to die from a fatal overdose. Furthermore
around 16% of deaths among newly released incarcerated individuals are due to fatal overdoses;
30% are due to suicide and 26% are due to heart disease. These stark statistics encapsulate the
failures within the criminal justice system to provide adequate mental and physical rehabilitation.

IIiiic. Homelessness and Increased Risk for Fatal Overdoses
Furthermore, individuals on the brink of homelessness or who are homeless and are
suffering from Opioid Use Disorders are at a higher risk of dying from opioid overdoses. A
study conducted by Yamamoto et al, compared opioid related outcomes between homeless
individuals and low income housed individuals. Homelessness brings many factors that increase
one’s risk of opioid related complications and death including: poor familial support,
physical/psychological burdens, environmental factors,…. From the study, they found that 1 in
10 homeless individuals who are admitted to the emergency department have an opioid related
disorder. Additionally, they found that individuals who are homeless are at a much higher risk of
opioid overdose and ED admission compared to individuals who are housed (1.8% versus .3%
and 10.4% versus 1.5% respectively) (Yamamoto, 2019). This high rate of OUD among
homeless populations may be correlated with increased drug usage due to physical/psychological
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burdens and the increased prevalence of laced drugs that are more accessible. It may also be the
fact that chronic opioid users may become homeless due to economic and social factors that
become present.
Furthermore, individuals who are homeless are less likely to receive treatment due to the
inability to access proper treatment and stigma surrounding homelessness and drug usage. Due to
the fact that current protocols within the ED settings do not decrease the risk of opioid deaths,
many patients are often repeatedly admitted to the hospital. Repeated hospital admissions and
inpatient treatment is costly for hospitals and will continue to be so until proper treatment can
become more accessible for populations most at risk. Increasing access to care for individuals
who are homeless is an imperative step in creating equitable public policies in order to decrease
the rate of fatal overdoses.
Purdue Pharma is just one example of the systematic discrimination and unethical
practices seen within major pharmaceutical and medical industries. Their immoral tactics have
led millions of individuals to become addicted to opioids. Furthermore, they are the reason
behind the economic impact of opioid use disorders in the United States, in which in 2017, alone
1,021 billion dollars have been spent on care for Opioid Use Disorders and opioid-related
fatalities (Luo, 2021). Populations at a higher risk of overdosing: newly released incarcerated
individuals, homeless individuals, and individuals with chronic pain have often been stigmatized
within the healthcare systems. It is equally important that multiple systems such as the criminal
justice system, public health care systems, and educational systems are able to provide education
surrounding OUD in order to increase awareness and reduce stigma around those who are
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suffering. Furthermore, increasing accessibility to MAT treatment and harm reduction resources
to populations most at risk is essential in tackling this epidemic.

III. Neurobiology and Pathology of Opioid Use Disorders

IIIi. Mechanisms of Action
Depending on the route of administration, the effects of the opioid/opiate may differ in
terms of its severity of effects and duration. At the same time, all opioids bind to particular
receptors in the brain and act out a series of steps that allow for the effects to take place. Opioids,
when administered, travel throughout the bloodstream to the brain. Opioids then bind to opioid
receptors in order to block pain signals and increase reward processes. When opioids activate
these reward processes, it triggers feelings of euphoria, which acts as a positive reinforcer
(Kosten & George, 2002). Due to the positive reinforcing properties of opioids, individuals tend
to continue using. Furthermore, the presence of withdrawal symptoms occurs due to repeated
exposure to escalating doses of opioids which alters the brain so that it functions abnormally
when opioids are not present (Opiate and Opioid Withdrawal, 2021)
The reward system is part of the major brain functions that are altered due to chronic
usage of opioids. The most common opioids are agonists meaning that they activate the receptors
that they bind to. These receptors are called mu opioid receptors. When attached, the effects of
the opioids take place (e.g. feelings of euphoria, pain reduction…) (Trescot et al., 2008). As
opioids bind to opioid receptors it releases high levels of dopamine (DA) into the nucleus
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accumbens (NAc) (fig. 3). The Ventral Striatum is in charge of the release of DA into the NAc
causing feelings of pleasure. Other areas of the brain create a lasting record or memory that
associates these good feelings with the circumstances and environment in which they occur. The
NAc’conditions the individual to associate opioids with positive/good feelings, which in return is
the beginning of a psychological dependence to opioids (Kosten & George, 2002).

Fig.3. The figure above shows the neurological pathways associated with opioid usage. The release of

dopamine into the NAc is associated with positive effects such as feelings of pleasure, decreased pain
signals, and euphoria. The figure also highlights other regions of the brain that are associated with opioid
usage (Trescot et al., 2008).

IIIii. Withdrawal Symptoms Explained
As previously mentioned, continued abuse of opioids dramatically decreases the effects
of the reward system. Due to a diminished response to pleasurable feelings, the individual will
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have to take a higher dose in order for the effects of the opioid to take place. Another key player
in the effects of opioids on the brain is the Locus Coeruleus. The Locus Coeruleus’s main role is
to release noradrenaline. Noradrenaline (NA) is a neurotransmitter that is involved in alertness,
vigilance, sleep, mood, and blood pressure. Normally, natural opioids that are produced in the
brain bind to the opioid receptor, which activates the conversion of adenosine triphosphate (ATP)
into cyclic adenosine monophosphate (cAMP). Cyclic adenosine monophosphate (cAMP) then
triggers the release of NA. When opioids bind to the mu opioid receptors, it diminishes the
function of the locus coeruleus, meaning that it inhibits the release of NA. As the user continues
to take opioids, the Locus Coeruleus will adapt to the brain function changes by increasing the
production of noradrenaline in order to cancel out the initial null effect. In the absence of opioids
in a chronic opioid abuser, the effects of increased amounts of noradrenaline create withdrawal
symptoms. Withdrawal symptoms are characterized by feelings of anxiety, headaches, chills,
fevers… Moreover, the presence of withdrawal symptoms from a clinical standpoint is the main
driving force behind repeated abuse of common opioids (Kosten & George, 2002).
The neurobiological changes that occur among chronic opioid users are important at
understanding the complexity of the disorder. When an individual develops a tolerance to their
drug of choice, their body has become dependent on the drug and without it, it cannot carry out
normal functions. Due to the neurological changes that occur, individuals cannot recover on their
own and need proper effective treatment in order to safely withdraw and recover. Furthermore,
the neurobiological changes that occur have a direct impact on one’s physical state, in which the
majority of individuals with OUD present with comorbid mental and/or physical health issues.
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IIIiii. Short Term and Long Term Negative Physical and Psychological Effects
Administering and abusing opioids can lead to numerous short and long term physical
and psychological effects. Around 45%-90% of users develop digestive issues such as
constipation and vomiting. The second most common physical effect is hypoxia, which occurs
due to the lack of oxygen distribution to the brain, and can lead to permanent brain damage
among other severe side effects such as coma and/or death. These short term physical effects can
lead to other complications that put an individual at an increased risk of serious illness.
Chronic opioid use is also associated with long term effects that are irreversible without
proper management and treatment. Endocarditis is one of the most common long term effects.
Infection endocarditis is an infection of the heart and is often present among heroin users. It has
been estimated that 20% of individuals who develop this infection will die. Additionally, blood
borne infections due to shared needle usage put individuals at risk for developing Hepatitis C,
HIV, and other diseases. Individuals who have developed an OUD are ten times more likely to
develop comorbid psychiatric disorders such as depression and/or anxiety along with other
comorbid addictions (Opioid Side Effects On The Brain & Body | The Hope House, 2020).
Co-occurring disorders are often linked to chronic usage of opioids and are needed to be treated
in order for the individual to properly recover and regain their life.
Lastly, opioid-related overdoses are very prevalent among chronic opioid abusers and are
responsible for the majority of opioid related fatalities. When an individual administers a higher
dosage of opioids than normal, it leads to respiratory depression. Opioids inhibit the necessary
activation of the medulla oblongata, which is in charge of normal respiration. Due to the
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inhibition of this region, individuals will present signs of severe respiratory depression along
with other symptoms such as: confusion, unconsciousness, pinpoint pupils, lack of motor
response… Without immediate medical attention, individuals have a high risk of mortality
(Opioid Overdose, n.d.).
Due to the underlying brain changes present in individuals with OUD, treatment for
opioid use disorders tends to be complex and long-term. As previously mentioned, withdrawal
symptoms that are present after an individual develops a tolerance are the main driving force
behind continued opioid usage. Current treatment protocol targets the presence of withdrawal
symptoms by diminishing their negative effects in order for individuals to detox from their
current drug of choice. Cravings are also linked to repeated usage of common opioids, in which
behavioral therapy and medication can decrease the intensity of cravings and environmental
triggers. Current treatment protocols for OUD have been shown to be effective though, due to
lack of treatment initiation and low retention rates current treatment protocols are not as effective
as they need to be.

IV. Effectiveness of Current OUD Treatment
Treatment for Opioid Use Disorders is extremely complex due to the underlying factors
that differ from one individual to the next. Chronic opioid abuse leads to brain changes that are
difficult to repair without proper long term treatment. On the frontlines of treatment, Medication
Assisted Therapy (MAT) has been the most beneficial treatment for individuals with Opioid Use
Disorders. MAT has long been the main treatment protocol for Opioid Use Disorders and uses
medication in conjunction with behavioral therapy in order to treat the individual. Another
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treatment for Opioid Use Disorder is MOUDS (medication for opioid use disorders) which
provides medication in order for the individual to detox. The length of treatment differs per
individual, but it is recommended that individuals receive treatment for at least 12 months.
Due to the length of treatment and the difficulties that individuals face during treatment,
there are high rates of treatment drop-out. According to a meta-analysis conducted by Sofuolgu
et al, they found that during the initial treatment induction phase, up to 40% of individuals
dropped out. Furthermore, after three months of treatment, the dropout rate goes up to 60%.
When examining effective treatment protocols, retention rates are crucial in evaluating the
efficacy of treatment. Retention is defined by compliance to treatment for a length of time that is
deemed suitable for the individual to regain their social, recreational, physical abilities… With
low rates of treatment retention, the benefits of treatment cannot be evaluated correctly. As the
current opioid crisis continues to make headlines, it is crucial that current treatment protocols for
Opioid Use Disorders should focus on increasing initiation and retention rates by providing
accessible pharmacotherapeutic and behavioral treatment (Sofuoglu et al., 2019).

IVi. Current Treatment Protocols: MAT/MOUDS
There are currently three pharmacological treatments for MAT/MOUDs approved by the
FDA to treat OUD: Methadone, Buprinephrone, and Naltrexone. Suboxone is also currently used
and is the combination of both Buprinephrone and Naltrexone. These medications are used in
conjunction with behavioral therapy in order for individuals to safely withdraw from the drug
they had been abusing along with developing and learning strategies to combat the underlying
factors that were at play during their addiction. The most common forms of behavioral therapy
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that are used in conjunction with medication are: contingency management, cognitive behavioral
therapy, support groups, and one-on-one therapy sessions. These modes of behavioral therapy aid
at increasing social functioning and retention.

IVii. Mechanism of Action for MAT
Firstly, Methadone is a synthetic full opioid agonist that binds to the mu-opioid receptors.
When it binds to the mu-receptor, it inhibits the presence of opioid withdrawal symptoms and
cravings. At the same time, the release of methadone in the bloodstream occurs much more
slowly than heroin or other opioids. The slowed release inhibits the onset of positive effects of
other opioids, though negative and positive side effects may be present within the induction
phase of methadone treatment (Connery, 2015).
Secondly, Buprenorphine is a partial opioid agonist with a high binding affinity and a
long duration of action. The majority of OUD cases can be managed with Buprenorphine.
Though it is most effective when individuals present mild/moderate withdrawal symptoms.
Buprenorphine binds to the mu opioid receptors but only partially activates with effects of the
binding. Buprenorphine’s effects are milder than the effects of methadone. Furthermore,
Buprenorphine can be administered by one’s physician, which increases treatment initiation.
While Methadone can only be administered in specific clinics (see annex p.61_). From a public
policy standpoint, the administration of Buprenorphine should be the first line in treatment
because of its favorable safety margin (Carley & Oesterle, 2021).
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Thirdly, there is naltrexone, which is an opioid antagonist. Opioid Antagonists inhibit the
function of the mu receptor in order for cravings to diminish. The issue that arises with
naltrexone is that one has to be completely detoxed in order to start treatment. Meanwhile,
Methadone and buprenorphine can be administered while the individual has not detoxed.
Additionally, Naltrexone does not produce a physiologic dependence that can be observed in
individuals treated with Methadone or Buprenorphine (Carley et al.,2021). Unfortunately,
naltrexone treatment is correlated with high dropout rates due to severe withdrawal symptoms
being present while being administered Naltrexone.
Lastly, we have Suboxone, which is the combination of Buprenorphine and Naltrexone.
Since the early 2000’s, there has been a rise in Suboxone clinics in order to treat OUD. The
combination of both FDA- approved drugs creates an opioid antagonist that manages cravings
and reduces symptoms of withdrawal. Furthermore, Suboxone treatment has been associated
with a decreased risk of dependency compared to methadone treatment (What Is Suboxone? 4
Facts Every Patient Should Know - Recovery Care, 2022).
Individuals with chronic OUD are at higher risk of developing physical and other mental
comorbidities. Individuals cannot recover on their own, meaning that long term patient- oriented
treatment is imperative. Additionally, treatment needs to consist of both medication (methadone,
buprenorphine, naltrexone, or suboxone) paired with more than one psychotherapeutic approach
in order for treatment to be effective long term.
As previously stated, current MAT treatment is effective at reducing opioid- related
fatalities and reducing drug usage, though there are many barriers that limit its accessibility and
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potential benefits (fig. 4). In a systematic review conducted by Hser et al, they analyzed whether
different MAT medications were more effective at retaining individuals in treatment. They
concluded that individuals randomized to the Buprenorphine (BUP) group had lower retention
rates compared to the Methadone (MET) group, though results were not statistically significant.
The varying retention rates were mainly due to the fact that in the Methadone treatment group
individuals had access to other health care and behavioral therapy support compared to the
Buprenorphine group. From this, treatment retention is influenced by the services provided in
treatment that aid in increasing motivation and compliance. At the same time, depending on the
severity of one’s disorder, different medications may be more beneficial. Due to Methadone’s
agonist properties, its effects are more favorable to certain individuals compared to others (Hser
et al., 2016). Due to the multiple factors that are associated with OUDs treatment, medication
alone does not increase retention and thus it needs to be in conjunction with behavioral therapy
and other health care services to increase its effectiveness.
Buprenorphine, Methadone , and Suboxone are the most commonly used medications in
MAT; their effectiveness depends mainly on individuals motivation and ability to complete
treatment. Methadone has been the golden standard for OUD treatment, though there are many
barriers that limit its accessibility. Buprenorphine, on the other hand, is able to become more
accessible because it can be prescribed by medical practitioners. Compared to Methadone, which
can only be administered in licensed MAT/MOUDS treatment centers. Additionally, suboxone
has also been shown to be an effective medication in combination with behavioral therapy.
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Fig.4. This figure shows that opioid use per month decreased in both randomized groups. Participants
who were in the Methadone group had fewer days of opioid use compared to the BUP group. At the same
time, both groups had a statistically significant decrease in opioid usage over the course of treatment and
post- treatment.
(Hser et al., 2016)

IViii. Current Psychotherapeutic Approaches for MAT

Substance Abuse Disorders such as OUD are complex disorders with overlapping
psychiatric, social, and legal problems. Behavioral therapy in conjunction with an FDA approved
medication has been shown to increase retention and effectiveness of treatment. As previously
stated, OUD’s may stem from certain risk factors such as poor familial support, trauma, abuse…
in which behavioral therapy addresses these issues in order to treat the “whole” individual.
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Evidence-based behavioral therapies have been shown to be effective at addressing underlying
problems and rewiring reward pathways.
Current behavioral therapies include: contingency management (CM), cognitive
behavioral therapy (CBT), motivational enhancement therapy (MET), and 12-step facilitation.
Furthermore, peer/community support via peer support meetings and therapeutic housing has
also been shown to be effective at reducing relapse rates. Medication alone has been shown to
not be an effective treatment measure due to the presence of comorbidities and heightened
cravings due to environmental triggers.

IViiia. Cognitive Behavioral Therapy
Cognitive Behavioral Therapy combined with medication has been shown to be effective
for individuals who have underlying psychiatric/health/social problems including: chronic pain,
anxiety, and depression. The main aspects of CBT is to provide education on the negative effects
of chronic opioid usage along with providing tools in order for individuals to reduce their
cravings and reactions to certain environmental triggers. CBT provides proper problem solving
and coping skills in order for the individual to be able to carry out “normal” social tasks. CBT is
often provided to individuals one-on one with a therapist, but it can also be used in a group
setting (Opioid Use Disorder | Fact Sheet, 2021).

IViiib. Contingency Management
Another evidence based effective behavioral therapy is contingency management.
Contingency Management (CM) uses operant conditioning in order to retrain individuals'
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reward pathways. When individuals come into a clinic, they are often screened for drug usage. If
an individual has a negative drug screening, they are rewarded with either a cash incentive or
some form of material good. Contingency management is a cost-effective behavioral therapy
approach. According to an investigation by Fairley et al., they found that MAT accompanied by
both contingency management and overdose education was both cost and time effective. It has
been estimated that in a cohort of 100,000 patients, without treatment there would be 42,717
overdoses and among them around 12,600 fatalities. Administration of Methadone was the most
effective form of medical treatment in reducing overdose rates. Followed by buprenorphine and
naltrexone. When accompanied by contingency management and overdose education, it resulted
in the highest rate of overdose reduction, though more research needs to be done in order to
access other treatment protocols (Fairley et al., 2021).

IViiic. Motivational Enhancement Therapy (MET)
Thirdly, Motivation Enhancement Therapy (MET) has been shown to be an effective
behavioral therapy that increases retention rates. Motivational Enhancement Therapy (MET) is a
counseling approach to increase one’s motivation to continue treatment. It is often used with
individuals who are ambivalent/ reluctant to treatment. MET occurs via meetings with a
therapist, in which the individual will learn proper coping mechanisms and reasons to quit their
drug of choice. Throughout the sessions, individuals are monitored in order to evaluate their
treatment response and motivation to continue receiving treatment. MET has been shown to
increase retention rates which in return would reduce drug usage and overdoses (Abuse, 2016).
In a study conducted by Dieperink et al., found that MET improved retention and abstinence
rates among individuals with Alcohol Use Disorder. From this randomized control trial, they
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found that abstinence rates increased in the experimental group (35% at baseline and 73% at
6-month follow up). Compared to the control group, abstinence rates increased only slightly
(35% at baseline and 59.5% at 6-month follow up). Considering that this study wasn’t analyzing
individuals with OUD disorders, it is still unclear what the efficacy of MET would be on
abstinence and retention rates (Dieperink et al., 2014).

IViiid. 12-Step Facilitation
Many substance abuse disorders are treated by a 12-step facilitation program in order to
increase compliance and motivation to change. Individuals undergo a series of steps in order for
them to be able to continue treatment and remain in treatment. The first step is acceptance of the
fact that one has a disorder. Secondly, due to chronic drug use and the neurological changes that
occur one has to seek medical and psychological support in order to recover. Alcoholism is the
main substance abuse disorder that incorporates the 12-step facilitation program. There needs to
be more research in order to evaluate the effectiveness of this behavioral therapy in conjunction
with medication for OUD (Abuse, 2020).
Medication alone for Opioid Use Disorder treatment has been shown to not be effective.
Medication needs to be paired with one or more forms of behavioral therapy in order to treat all
the factors that may be associated or impacted due to addiction. Furthermore, these behavioral
therapies aid at rewiring the reward processes in order for one to not depend on the drug they had
been abusing. Additionally, by increasing compliance and motivation through Motivational
Enhancement Therapy and Contingency Management retention rates may increase, which would
in return reduce the rate of relapse and fatal overdoses.
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V. Opioid Use Disorder Treatment: Comparison of Current Versus Novel Strategies
Vi. Importance of a Whole Patient Treatment Approach

Fig.5 (“Whole Person” Approach Needed to Solve Opioid Epidemic, Says APA, n.d.)
The figure above shows the various components of drug abuse treatment. Within the principal framework
of treatment, assessing and creating a treatment plan for the individual should include multiple health,
social, and mental health treatment options that would best suit the individual’s needs.

When it comes to providing long- term effective treatment for individuals with OUD, it is
imperative that treatment is individualized in order to meet the needs of the patients. It has been
shown that individuals who remain in treatment over an extended amount of time report
decreased criminal activity, improved social/psychological functioning, and stop drug usage
(fig.6). Compliance to treatment is increased when an individual is treated by a “whole patient
approach”. A whole patient approach is characterized by accessing the multiple factors that are
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associated with one’s OUD along with resources to aid the individual in accessing and retaining
in treatment.
Furthermore, the American Psychological Association has stated that the most effective
treatment involves both pharmaceutical and psychotherapeutic treatment. Behavioral therapies
such as contingency management, cognitive behavioral therapy, and multidimensional family
therapy are the most effective forms of therapy. Concluding that treatment initiation and
retention strategies for opioid use disorders needs to revolve around effective pharmaceutical and
psychotherapeutic approaches in order to treat “the whole individual” (“Whole Person”
Approach Needed to Solve Opioid Epidemic, Says APA, n.d.).

(Fig.6) The study conducted by Chan et al, found that participants with OUDs who remained in treatment
reported an increase in quality of life, improved health, and reduced mortality. (Chan et al., 2021)
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Vii. Addressing the Current Treatment Gap

Opioid Use Disorders are the most deadly mental health disorders. On average, 100
individuals die from opioid- related overdoses daily. Among them the majority of them were
chronic opioid users. Additionally, OUDs are correlated with negative social/psychological
problems, poor health, increased risk of death/serious illness etc… As rates of OUD continue to
rise it is important to analyze the effectiveness of current treatment in order to evaluate the
changes that need to be made in order to increase initiation and retention rates.
Current treatment for Opioid Use Disorders has been shown to decrease fatalities, though
the main issue at hand is the current treatment gap and low retention rates. A study conducted by
Amura et al., found that death rates among individuals in MAT treatment are 75% lower than
those who had left treatment. Furthermore, in the US alone, 2.5 million individuals are in need
of treatment, in which they either do not admit themselves or do not have access. Additionally,
individuals who are admitted to treatment with lack of motivation are at a higher risk of relapsing
which can lead to an increased risk of death.
Treatment for Opioid Use Disorders need to implement different strategies in order to
increase treatment initiation and motivation enhancement in order for retention rates to increase.
As States are receiving more money in order to combat this pressing public health crisis, it is
important that effective policies are implemented (Amura et al., 2022).
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Viia. Factors Contributing to The Current Treatment Gap
Understanding individuals needs and past opioid usage is important in assessing
treatment options that would correlate with increasing retention rates. Furthermore, it is
imperative that current treatment should become more accessible in order to narrow the current
treatment gap.
The current treatment gap has been caused by numerous factors. For one, there aren’t
enough treatment centers in order to treat millions of individuals with OUD. In a study
conducted in 2017, almost 70% of individuals with OUD did not receive treatment. On top of
that , depending on an individual's consumption and severity of their addiction, different MAT
medication should be used in order to meet the needs of the individual. Unfortunately, the
majority of the clinics that administer MOUDS/MAT treatment only offer one type of
medication. Moreover, only 32% of clinics in the United States administer all medications.
Considering that individuals respond differently to medication dependent on their past drug
usage and other variables, there should be more than one option for medication. There are fewer
than 1700 methadone clinics, in which only 380,000 individuals are able to be treated.
Meanwhile, 2.5 million individuals are in need of treatment. As previously stated, Methadone
has been shown to be more favorable in treating Opioid Use Disorder and has been linked to
increasing treatment retention (Donroe & Tetrault, 2018). At the same time, more research needs
to be done in order to fully assess the effectiveness of different medications on different types of
individuals. Unfortunately, mainly due to access barriers, administration of methadone is limited
and does pose a safety concern due to increased risk of respiratory depression and other negative
side effects.
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Buprenorphine on the other hand, has a much favorable safety margin and can be
administered by certified health practitioners. Buprenorphine has also been an effective mode of
treatment for individuals with chronic pain and individuals who haven’t responded positively to
methadone. Buprenorphine administration could be a lot more accessible because primary care
doctors and other medical practitioners have the ability to become certified in order to provide
care for their patients. Unfortunately, it has been estimated that only 13% of clinicians are
certified to prescribe Buprenorphine. This is mainly due to insufficient training in assessment
and treatment of Opioid Use Disorders along with stigma surrounding individuals with OUD.
Additionally, due to lack of knowledge and other barriers such as restrictions on the part of the
organization that provides waivers to medical practitioners has made it more difficult for medical
practitioners to become certified. Additionally, time, money, travel , and motivation all play a
part in whether one is willing to be admitted into treatment and for them to remain in treatment.
Traveling and schedule conflicts pose a major barrier when it comes to treatment, in which many
clinics will dismiss patients due to lack of attendance, which decreases the accessibility aspect of
treatment (Stokes & Perrone, 2022).
Despite all these barriers, there are policies that are being implemented in cities
throughout the United States in order to address and decrease the current treatment gap, and to
offer effective treatment to populations at risk.

Viia. Current MAT Treatment Effectiveness
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Effective treatment for Opioid Use Disorder is now a national priority in order to reduce
the rates of fatal overdoses, societal costs, and individual disabilities linked to this disorder.
In a meta-analysis conducted by Connery et al., they analyzed multiple randomized control trials
(n=502) in order to determine the effectiveness of current OUD treatment. They found that
individuals treated with Methadone had higher retention rates and lower opioid usage compared
to Buprenorphine and Naloxone.
At the same time, Methadone treatment has been associated with several negative side
effects such as “sedation, constipation, sweating, neurocognitive impairment, and sexual
dysfunction”(Connery et al, 2015). They also found that within the initiation period, euphoric
effects can be present among individuals, which may encourage the usage of other opioids.
Individuals randomly controlled to the buprenorphine group presented fewer side effects,
in which only mild respiratory depression was present in only a few cases. Additionally,
Methadone has numerous drug interactions due to the enzymes involved in its metabolization.
Both Buprenorphine and Naltrexone have fewer drug interactions. Moreover, methadone takes
time to achieve a steady-state dose that is considered therapeutically effective, which can be
associated with an increased dropout rate due to effects associated with misdosaging methadone.
Compared to Buprenorphine, Suboxone, and Naltrexone that have a rapid induction period and
are correlated with reduced undesirable effects (Connery, 2015).
Undesirable effects that are often presented within the treatment induction phase
( 1-month treatment) may correlate to the high dropout rate. In order to reduce current dropout
rates, individuals need to be properly assessed in order for their treatment plan to be more
adaptable to their needs. From the meta-analysis conducted by Connery et al., they examined
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various factors that play a role in the effectiveness of current medication treatments in relation to
retention. Factors such as clinical setting, access, therapeutic preferences, occupation,
comorbidities, and motivation should all be considered when assessing treatment needs
(Connery, 2015). Properly assessing an individual using a “whole patient approach” is an
imperative aspect in creating treatment frameworks.

Viii. Increasing Outcomes Dependent on Opioid Usage
Another aspect that should be considered when developing individualized treatment
protocols is assessing which type of opioid was being abused. A study conducted by Moore et
al., found that individuals who had been abusing painkillers (e.g. oxycodone/ hydrocodone)
responded more positively to Suboxone treatment compared to heroin users in the same
treatment group. They found that 59% of individuals who had been abusing prescribed pain
killers completed treatment, compared to 30% of heroin users (Moore et al., 2007). Another
study conducted by Anderson et al., found that methadone maintenance therapy was most
effective for individuals with chronic pain and who had been abusing heroin because of its
analgesic properties (Anderson & Kearney, 2000). Factors such as past drug usage should be
assessed in order for individuals to receive the medication that would benefit them best.
Unfortunately, the majority of studies do not account for various characteristics and variations in
response to settings where participants have received treatment.
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Viiii. Increasing Buprenorphine Administration

As previously stated, Medical Practitioners are able to become certified in Buprenorphine
administration for MAT treatment. Medical practitioners are one of the main groups of
individuals that are faced with handling patients with OUDs. Medical practitioners, such as
primary care doctors, should be allowed to treat and monitor individuals with OUD.
To begin, buprenorphine can be prescribed by one’s primary care doctor. In order to be
approved to administer Buprenorphine, practitioners must complete a waiver in order to be
certified. Receiving the certification of approval isn’t complex, though there are underlying steps
that limit one’s ability to administer buprenorphine to everyone. Implementing educational
programs for medical students could potentially increase treatment initiation by educating future
medical providers to provide Buprenorphine to patients with OUD . In 2018, multiple
departments in charge of Substance Abuse Disorder Prevention and Recovery funded medical
schools in order to educate students in order for them to meet waiver training requirements.
Additionally, there have been some efforts in order to decrease the amount of steps one has to
take in order to be able to administer buprenorphine.
Increasing the number of medical practitioners that could administer buprenorphine could
potentially decrease the current treatment gap and increase treatment initiation. Medical
practitioners could play a major role in treating individuals with OUD, especially those who
have a history of abusing prescribed narcotics (Anderson & Kearney, 2000). Additionally,
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patients often have a rapport with their primary care doctor which could aid in increasing
treatment compliance and motivation.

VI. Novel Strategies at Increasing Treatment Initiation

Increasing treatment initiation is a difficult but necessary step in addressing the current
opioid crisis. Populations most at risk for fatal overdoses need to be prioritized in the making of
newer public policies that address the Opioid Crisis. Vulnerable populations, such as newly
released incarcerated individuals, homeless individuals, are often put on the back burner when it
comes to public crises, in which millions of individuals disproportionately suffer the
consequences of unequal policy changes.
Treatment initiation protocols and other forms of harm reduction educational programs are
essential in reducing the risk of fatal overdoses. The lack of accessible treatment and stigma
surrounding substance abuse disorders are at the root of the current treatment gap. Furthermore,
current policies within the health care and justice systems fail to address the needs of populations
most at risk.

VIi. Novel Initiation Strategy: CATCH
The majority of individuals with OUD end up in the emergency department before they
seek treatment. Current Emergency Department protocols do more harm than good. The current
protocol in Emergency Departments is to medically detox the individual and discharge them.
The current protocol isn’t effective and increases the risk of fatal overdoses due to lack of
therapeutic intervention and decreased tolerance. A pragmatic study conducted by Mckneely et
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al., addresses the failure of current Emergency Department Protocols and assesses a novel
approach to treatment initiation.
In New York City, public policy officials have implemented a new program in 6 public
hospitals that targets individuals who are admitted to the Emergency Department. A study
conducted by McNeely et al., analyzed a novel initiation program called CATCH. CATCH stands
for “Consult for Addiction Treatment and Care in Hospitals'' and aims at initiating OUD
treatment to patients who come to the emergency room due to an opioid- related overdose or
other medical problems associated with opioid usage. Patients who are admitted are met with the
CATCH team, which consists of: medical provider, social worker/addiction counselor, peer
counselors. Patients will be assessed by a medical provider in order to make treatment
recommendations that cater to the individual's needs. During the same period, both a social
worker and an addiction counselor will meet with the patient and provide motivational
counseling and treatment options. Additionally, patients will receive overdose prevention
training. One of the team members would then bring the patient to an outpatient treatment
facility in order for them to receive their first dosage of MAT medication. This approach not
only targets at-risk populations but treats the patient as a “whole individual”.
The pragmatic study aimed at analyzing whether this new program was effective and
whether that adoption, implementation, and maintenance could be observed. They found that this
program not only increased treatment initiation but also increased treatment retention. The study
analyzed treatment retention at 6 months and found that 80% of individuals remained in
treatment.
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Programs such as CATCH are not only effective at targeting at-risk populations, but are
also cost effective. It has been estimated that 11 billion dollars are spent on treating individuals
with OUD annually (Premier, 2022). Individuals who are admitted into the hospital often
present with complicated physical illnesses. Around 40% of cases deal with organ failure. Organ
failure requires extensive ICU care that is often expensive. Furthermore, readmission rates are
high due to lack of proper treatment. The current Emergency Department protocol for patients
with opioid related complications correlates with a 90% relapse rate and a higher risk of fatal
overdose due to reduced tolerance and lack of overdose education. CATCH has the possibility to
drastically reduce opioid-related fatalities, readmission hospitalization costs and further target the
current Treatment Gap (McNeely et al., 2019).

VIii. Treatment Initiation: SHOW
Another program similar to CATCH has been initiated in New York City as well. The
program is called SHOW (Street Health Outreach and Wellness) which has been funded by the
Test and Trace Corporation. The Test and Trace Corporation was the main organization in NYC
that managed the current Covid-19 public crisis. SHOW targets at-risk populations, mainly
individuals who are suffering from homeless and other disabilities. They provide Covid-19 tests
and vaccinations, basic medical aid, and harm reduction resources. SHOW is able to target the
needs of homeless individuals and provide them with effective equitable care.
Moreover, the organization is composed of multiple team members in order to provide
individualized services for individuals with Opioid Use Disorder. The team is made up of nurses,
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EMT’s, and social workers. This team provides extensive resources to those who are suffering
from homelessness. For one, they provide overdose education training along with distributing
Narcan and fentanyl test strips, sterile needles... They also will provide individuals with a full
physical and mental exam. Secondly, they provide mental and physical assessments in order to
provide proper care to individuals. They also assess individuals in order to provide them with
referrals to treatment centers along with providing additional support if needed.
SHOW is an organization that increases accessibility to treatment and harm reduction education.
Current harm reduction educational programs have been shown to be effective at
educating individuals on opioid overdose prevention, though there are some drawbacks. Harm
reduction in the form of educational training has been shown to be effective at educating
individuals, though these educational programs often do not target at-risk populations such as
homeless individuals. Harm reduction training and education is imperative in reducing the rate of
fatal overdoses by providing resources and Narcan in order to prevent fatalities. A study
conducted by Heavy et al., in 2018 found that harm reduction in the form of Overdose Education
and Naloxone (Narcan) distribution (OEND) is an effective harm reduction approach, though
the program does not target at-risk populations. The participants in the study (N=198) attended
training sessions in order to learn about the signs of an overdose, and how to administer Narcan.
Participants at the end of the training were more informed about opioid related overdoses and
how to reverse the effects using Narcan. The majority of the participants were not individuals
who had relationships with opioid users (Heavey et al., 2018). From this, providing overdose
education resources can dramatically reduce the rate of preventable fatal overdoses from
occurring.
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SHOW dedicated team of medical and mental health care providers are able to deliver
effective resources to at-risk populations. Not only are they providing resources on harm
reduction strategies (e.g. narcan, fentanyl test strips, clean needles…), they also help individuals
who are willing to start treatment to be referred to an outpatient Buprenorphine treatment center
or to other resources that may provide mental and physical care (The NYC Test & Trace Corps
Launches Buprenorphine Treatment Pathway From Harlem To Hollis To Help With Opioid Use
Disorder, 2022).
If more cities implement programs such as CATCH and SHOW it could potentially be a
major step forward in effective equitable public health care.

VIiii. Increasing Access to Treatment within the Criminal Legal System
The Criminal Legal System is another system that needs to provide Opioid Use
Treatment and overdose prevention training for incarcerated and newly released incarcerated
individuals. America’s war on drugs has fueled the prison industry and has perpetuated
discriminatory practices within the criminal justice system. Furthermore, substance abuse
disorders are one of the major disorders that are present within the prison system. It has been
estimated that around 24%-36% of individuals who abuse heroin pass through one or more
correctional facilities annually, which amounts to about 200,000 individuals each year. Due to
improper treatment, many of these individuals will undergo severe withdrawal symptoms that
perpetuate increased drug usage within correctional facilities. Recent research done by
SAMHSA, found that 75% of individuals who have a history of opioid abuse relapse when they
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are released. Due to diminished tolerances, and that more illicitly made drugs are laced with
fentanyl , these individuals are 10 to 40 times more likely to die from an opioid overdose.
In addressing the rates of fatal overdoses among newly released inmates, more Opioid
Use Disorder Treatment (MAT) needs to be implemented. Within the study conducted by
SAMHSA, only 2 to 10% of released incarcerated individuals with OUD were in MAT
treatment. Additionally, around 50% of drug courts have prohibited individuals from receiving
Methadone or Buprenorphine (see figure 7). The purpose of Drug Courts is to provide
individuals with treatment for substance abuse disorders and their current protocols are not
adapted to the needs of individuals and has led to 80% of individuals not completing Drug Court
requirements. Moreover, the extremely small percentage of released incarcerated individuals
receiving MAT treatment demonstrates the ineffectiveness of current prison systems at
“rehabilitating” individuals in order for them to return back to society. Furthermore, the strict
protocols administered within the Drug Court perpetuate barriers that inhibit one from receiving
treatment and further perpetuate rates of addiction. Providing proper treatment that provides both
pharmacological and psychological behavioral therapies along with harm reduction education
programs could potentially decrease the rate of fatalities, improve quality of life, and reduce the
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rate of reincarceration.

Fig. 7 The figure above illustrates the lack of Opioid Use Disorder treatment within the criminal justice
system. There are many factors that are at play, such as the discriminatory practices present within the
criminal justice system, lack of education, stigma surrounding addiction and addiction treatment…
(Breaking the Cycle, n.d.).

Public Health organizations such as SAMHSA have been at the forefront of
implementing Opioid Use Disorder treatment within the Criminal Justice System. Providing
MAT to individuals who have been assessed for OUD and allowing them to complete treatment
within the correctional facility could decrease the risk of fatal overdoses once released.
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Furthermore, providing continuative care once individuals are released would also decrease the
chances of relapse and re-incarceration. It has been shown that individuals suffering from past
Opioid Use Disorder are much more likely (40-50% of individuals ) to be reincarcerated within a
couple months of their release.
There are many barriers in the way that inhibit MAT from being provided within the
criminal legal system. Barriers such as: lack of knowledge, current policies not supporting MAT,
security and liability concerns, and cost. These barriers will continue to be upheld unless proper
policies can be implemented. On the other hand, in 2019, SAMHSA funded multiple judicial
systems in order for them to incorporate OUD treatment. Current drug court protocols often do
not provide adequate treatment for individuals with OUD and often prohibit individuals from
receiving MAT. SAMHSA has funded 42 adult drug courts, 12 family drug courts, and two
programs to provide MAT. Implementing MAT within the current criminal justice systems
could correlate with a drop in reincarceration and fatalities (Breaking the Cycle, n.d.).

VII. Treatment Retention Strategies
Funding for Public Health policies that target at-risk populations is an essential part in
reducing the rate of opioid- related fatalities as well as increasing treatment initiation.
Populations that are at a higher risk of opioid- related fatalities are in need of more accessible
and effective care in order for rates of fatalities to decrease. Opioid Use Disorders are often
chronic illnesses, in which relapses are part of treatment. Increasing retention rates would not
only further decrease the current treatment gap but also increase one’s ability to return to a
“regular” life.
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Current treatment protocols are unfortunately associated with high rates of dropouts
which limits the effectiveness of current MAT/MOUDS. There are many factors associated with
the high dropout rates such as: lack of behavioral therapy, poor familial support, transportation,
scheduling conflicts, presence of withdrawal symptoms, and strict protocols. Increasing initiation
and retention within a whole patient approach to treatment frameworks is an important next step.

VIIi. Novel Retention Strategies

Increasing treatment initiation has the possibility to increase retention rates as well.
Depending on how individuals are admitted into treatment and what types of medication and
psychotherapeutic approaches are available correlates with retention rates. The “whole patient
approach” (p.32), increases retention rates because of improved motivation and compliance to
treatment. Additionally, a harm reduction approach to treatment also improves retention rates
because of its patient-centered approach.
Harm reduction programs are making headlines due to their ability to save lives. Harm
reduction as a whole aims at meeting individuals where they are and providing: sterile injection
needles, narcan training/overdose prevention education, fentanyl test strips, and more in order to
reduce the rate of blood-borne infections and preventable fatal overdoses. A harm reduction
approach to treatment differs from current treatment protocols, in which the patient has more say
in their treatment plan along with increased access to primary and mental health care.
Oftentimes, within treatment facilities, individuals may still continue to abuse drugs. Since
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Opioid Use Disorders are chronic disorders, relapses are part of treatment. Current protocols
implemented within healthcare models for Opioid Use Disorder treatment are often strict and do
not put an emphasis on patients' needs. It has been shown that 30% of involuntary buprenorphine
treatment drop-outs are linked to poor attendance and/or positive drug screenings. (Kapedia,
2021 ). A study conducted by Bruneau et al., found that by retaining individuals who’ve had
positive drug screenings in treatment, drastically reduces their risk of harm and increases
retention rates (Bruneau et al., 2018).
The harm reduction philosophy, when applied to healthcare settings, has the potential to
reduce stigma around substance use disorders in order to increase accessibility and effectiveness
of treatment. A program called REACH (Respectful, Equitable Access to Compassionate
Healthcare) provides treatment that implements a harm reduction philosophy. REACH provides
patients with primary care services, mental health services, and social services (fig.8).
Additionally, REACH provides funding to healthcare providers in order for them to become
certified in prescribing and administering Buprenorphine (Respectful and Equitable Access to
Comprehensive Healthcare Program | Mount Sinai - New York, n.d.). Providing a multitude of
resources to individuals with OUD is crucial in treating the physical and mental ailments that
may be present.
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Fig.8. The services provided in the model above aid at increasing treatment retention. Individuals with
OUD often are in need of additional physical, social, and mental health services in order to recover
(Respectful and Equitable Access to Comprehensive Healthcare Program | Mount Sinai - New York, n.d.).

VIIiii. Implementing a Harm Reduction Philosophy
The current healthcare model for OUD treatment increases barriers that dismiss
individuals from receiving long term individualized treatment. These barriers further impose
stigma around substance abuse that perpetuated the continued cycle of abuse. Furthermore,
within the current framework of OUD treatment, the institution and the medical providers have
more say over treatment plans compared to their patients. Current protocols may not take into
account individuals personal needs and wants when it comes to receiving treatment. By
removing these barriers and including a harm reduction philosophy into current treatment
models, along with providing adequate social/health/mental care to accompany MAT treatment
retention rates would increase. Furthermore, patients would not be dismissed due to lack of
attendance and/or positive drug screenings. Instead, these individuals would be provided with
resources in order to potentially increase compliance and motivation to change.
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VIIiiii. Reducing Barriers: “Treatment On Demand”

Individuals with Opioid Use Disorder may drop out of treatment due to scheduling
conflicts. Scheduling around treatment often interferes with individuals lives and
social/familial/work obligations. The study proposed that “Treatment on Demand” allows for
flexible scheduling and can be associated with reduced wait times, increased initiation and
retention. Furthermore, within this low-barrier approach to MOUD (Medication for Opioid Use
Disorder), the incorporation of non-clinical support such as behavioral therapy, peer support
groups, family therapy would be available for patients as well. Additionally, in order to increase
flexibility, psychotherapeutic approaches could happen via telemedicine or via text messages.
Decreasing barriers and increasing access to treatment via treatment on demand, flexible
scheduling, patient oriented approach, and access to telehealthcare has the possibility to increase
treatment initiation and retention (Madras et al., 2020).

More supporting evidence for the effectiveness of the Harm Reduction Model for OUD
within a primary care setting can be shown in the study conducted by Bruneau et al. Within this
study, they analyzed the effectiveness of treatment protocols that align with the Harm Reduction
Approach. Within this analysis they lay out a model of care (fig.9) that implements different
lines of treatment in conjunction with harm reduction education (Bruneau et al., 2018).
Within their analysis, they created a treatment model that would increase initiation and
retention rates. To begin, Suboxone (Buprenorphine -Naloxone) should be the first line of
pharmacological treatment because of its favorable safety margin and its ability to be prescribed
within a primary care setting. Additionally, Suboxone can be brought home in order to increase
treatment flexibility. Individuals who do not respond positively to Suboxone would then be
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administered Methadone. They also assessed the effectiveness of different pharmacological
treatments dependent on individuals' drug usage. They found that individuals who have been
abusing prescription pain medication respond best to Suboxone or Buprenorphine compared to
heroin users. Methadone as a second line to treatment often works best for individuals who have
been abusing heroin and/or fentanyl.
Additionally, within this study they analyzed another pharmacological approach to OUD
treatment. Individuals who do not respond to both the first (Suboxone) and second (Methadone)
line of treatment can be administered slow-release morphine. Previous meta-analyses have found
slowed release Morphine does not decrease retention rates compared to Suboxone and
Methadone treatment (Bruneau et al., 2018)

Fig. 9.The model above outlines the treatment model discussed in the Bruneau et al study.
Individuals diagnosed with OUD should be assessed in order to better evaluate the severity of their
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disorder. Depending on the severity of one’s disorder, Opioid Agonist treatment may differ (Suboxone,
Methadone, or Slow-Release oral morphine). Psychosocial treatment should also be offered in order for
factors that are at play within one’s substance abuse disorder to be properly addressed. (Bruneau et al.,
2018)

VIIiiiii: CDC’S Response to increasing OUD Treatment Effectiveness

In 2022, the CDC released a guiding framework to prevent Opioid Overdoses and other
Harm related to Substance Abuse Disorders. The current Covid-19 pandemic has exacerbated the
Opioid Crisis, in which opioid-related deaths are the leading cause of injury-death. They’ve
identified numerous factors that are at play in the drastic increase in deaths. For one, there has
been a drastic increase in polydrug deaths, in which individuals often suffer from one or more
substance abuse disorders. Comorbidities increase one’s risk of overdosing due to the increased
presence of laced drugs that are being sold.
The CDC’s work at addressing the current Opioid Crisis is guided by six principles. For
one, promoting health equity, in which everyone has access to harm reduction educational
programs and treatment. Programs such as CATCH, SHOW, REACH, and SAMHSA's treatment
initiation strategies increase access to said resources and target at-risk populations that have been
stigmatized and ostracized by current healthcare protocols. Secondly, Addressing Underlying
Factors such as physical and mental health disorders and creating a framework of care that
targets these factors can increase the effectiveness of current treatment protocols. Implementing a
harm reduction approach that is geared towards Patient Oriented Treatment Plans in conjunction
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with psychotherapeutic and physical health support can potentially drastically decrease the rate
of fatal overdoses and comorbidities. Thirdly, Partner broadly, in which multiple systems
implement targeted strategies to reduce Harm. Systems such as the Criminal Justice System,
Educational Systems, and Public Health Care systems have the possibility to increase education
and treatment initiation programs to target at-risk populations in order to increase treatment
initiation and retention rates. Fourthly, “Advancing Science” which can be seen by continuing to
research treatment options in order to offer more effective and accessible treatment options to
individuals with Opioid Use Disorders and other Substance Abuse Disorders. Lastly, “Drive
Innovation”, in which novel strategies should be evaluated in order for them to become
implemented within current treatment protocols (MAT/MOUDS).
The Initiation Strategies and Retention Strategies discussed in Chapter 6 and 7 have
addressed these guiding principles and have paved the way for more accessible treatment options
to be available to populations most at risk. Increasing harm reduction education and resources to
at-risk populations and increasing treatment options via a Primary Care Model have the
possibilities to break down the current barriers that are at play in the current Treatment Gap.
They are all evidence based and target various systems that are at play within the Current Opioid
Crisis.
There are also five strategic priorities to address the Overdose Crisis. For one: Monitor,
Analyze and Communicate Trends, in which statistics and field research needs to continue in
order for resources to be focused on where they are needed most. Secondly, Build State, Tribal,
Local, and Territorial Capacity, in which public health leadership needs to collaborate with
various sectors in order to detect drug usage trends, promote education, and prevent overdoses.
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Support Providers, Health Systems, Payors, and Employers in order to prevent opioid misuse and
abuse and mitigate stigma surrounding Substance Abuse Disorders within the current Healthcare
Model. This can be seen by increasing education around Buprenorphine prescription certification
and administration within a Primary Care Setting. Additionally, programs such as CATCH and
SHOW have the ability to reduce gaps in treatment and targeting at risk populations. Fourthly,
Partner with Public Safety and Community Organizations in order to increase partnerships
through public health strategies on a national, state, and local level. SAMHSA's strategy to
increase access to treatment within the criminal system increases the link between individuals
and treatment along with reducing the current treatment gap and addressing risk factors. Lastly,
Raise Public Awareness and Reduce Stigma in order for barriers within current health care
systems to be dismantled. Stigma surrounding substance abuse disorders is at the root of the
current treatment gap and disables individuals from seeking treatment in the first place.
Increasing awareness and education surrounding the Opioid Crisis has the potential to mitigate
biases and prejudices against individuals with Opioid Use Disorders. Implementing a patient
orientated approach to treatment increases compliance to treatment and autonomy to treatment,
in which the individual has more trust and motivation in treatment. Additionally, a harm
reduction approach reduces stigma around Substance Abuse Disorders by understanding the
complexity of the disorder and the fact that it is a Chronic Disorder with multiple factors at play.
Endorsing non-stigmatizing language in a patient-oriented approach to treatment could improve
motivation.
As more states begin to implement these guidelines, it is also imperative that populations
most at risk are targeted. The current barriers such as lack of education and stigma surrounding
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Opioid Use Disorders further enable the current crisis to evolve and worsen. The strategies
previously mentioned have implemented these guiding principles and strategies in order to
decrease harm and increase initiation and retention rates.

VIII: Discussion
In 2021, fatalities due to opioid overdoses reached a record high in which 100,000
individuals died. These overdoses could have been prevented. The introduction of prescription
opioids into the United Healthcare system is at the root of this statistic. Purdue Pharma and their
unethical practices of persuasion led millions of doctors to prescribe opioids despite their
historically known addictive properties. Populations who were most susceptible to addiction
were first targeted due to high rates of chronic pain and their ability to increase profit. There
were very few measures implemented in order to analyze and assess individuals risks of
Oxycodone misuse.
Anyone who is prescribed oxycodone has a risk of developing an addiction. Individuals
with chronic pain, homeless individuals, newly released incarcerated individuals with OUD, are
at a much higher risk of overdosing. Implementing strategies that target these populations in
order to increase treatment initiation and retention is imperative.
A “Whole Patient Approach'' and patient- oriented framework and the inclusion of a
Harm Reduction Philosophy to current MAT treatment has the potential to increase the
effectiveness of current MAT treatment. Moreover, increasing the administration of
Buprenorphine within a Primary Care setting can also increase treatment initiation and reduce
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the current treatment gap. Along with implementing MAT treatment within an Emergency
Department setting could drastically reduce the rates of readmission and fatalities associated with
opioid overdoses. From previous research, Burprenorphine and Suboxone are more favorable in
terms of their ability to provide care in more settings. At the same time, depending on one’s past
drug usage individuals should be able to be administered Methadone which has been shown to
increase retention among heroin and fentanyl users. Medication always needs to be paired with
some form of behavioral therapy along with physical, social, and mental health care in order to
treat the individual as a whole.
Moreover, increasing MAT treatment within the criminal justice system could reduce the
risk of fatal overdoses for newly released inmates along with reducing the rate of reincarceration.
SAMHSA has been pushing policy makers into implementing MAT treatment within the
criminal justice system along with providing continuative care once inmates are released.
Furthermore, they have funded numerous programs in order for MAT and other social services to
be implemented within the Criminal Justice System. Increasing MAT treatment and other modes
of social services surrounding substance abuse disorders like OUD within the justice and prison
systems could potentially drastically decrease the rate of fatal overdoses and reduce the current
cost associated with imprisonment.
Unfortunately, due to limitations in research and understanding the effects of Opioid Use
Disorders on different populations, we cannot conclude that one form of treatment is better than
others. Creating treatment frameworks that are geared towards a patient oriented approach has
been shown to be effective at increasing retention rates. Additionally, providing Buprenorphine
as the first line of treatment is more accessible compared to Methadone. At the same time,
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individuals who have a history of abusing more potent opioids such as heroin and/or fentanyl
often respond more positively to methadone treatment. Meaning that treatment needs to be
individualized, which could pose a major economic hurdle within healthcare facilities.
Furthermore, individuals who suffer from a chronic Opioid Use Disorder often present other
substance abuse disorders and comorbid mental health disorders. As more research is being
conducted throughout the United States, it is important that treatment should address and provide
adequate care and support for individuals with comorbid substance abuse and mental health
disorders. Additionally, due to barriers within many systems that need to provide MAT treatment,
it may be more difficult to implement treatment protocols due to restrictions within these
systems. Moreover, in order to properly evaluate the efficacy of novel treatment strategies, more
states need to implement them in order to assess their overall effectiveness.
As more states receive funding in order to address the Current Opioid Crisis, they should
implement strategies that have been shown to reduce the treatment gap and provide equitable
MAT treatment to populations at risk. Organizations such as CATCH, SHOW, REACH, and
SAMHSA have implemented public health policies that decrease barriers in accessing treatment
and provide individuals with continuative MAT treatment.

Conclusion
The Opioid Epidemic is long from being over. Due to the continued prescription of
oxycodone and other prescribed opioids, we will continue to see increased rates of Opioid Use
Disorders. Additionally, as more street drugs continue to be laced with fentanyl, the rate of fatal
overdoses may continue to rise. In order to tackle the epidemic, we need to address those who

CROSSROADS IN THE OPIOID EPIDEMIC

59

are already suffering from Opioid Use Disorder. Along with providing more harm reduction
resources to populations most at risk. Providing both harm reduction resources and increased
access to equitable treatment via the strategies previously mentioned could be a major step
forward in combating the crisis.
Implementing more treatment options involving a Whole Patient Approach, a Patient
Oriented Approach, and a harm reduction philosophy could drastically decrease the current
treatment gap and increase retention rates. As retention rates increase, the more effective MAT
treatment would be. Additionally, by providing more education surrounding OUD in primary
care facilities could increase the administration of Buprenorphine in order to decrease the current
treatment gap. Creating effective models of care for individuals with Opioid Use Disorders is
important in order for more states to implement equitable treatment frameworks.
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Appendix

Diagnosis of Opioid Use Disorders
According to the DSM-5, in order to be diagnosed with OUD one has to meet one or more of
the following criteria over a 12-month period.:
1.
2.
3.
4.
5.
6.
7.
8.
9.

Taking larger amounts or taking drugs over a longer period than intended.
Persistent desire or unsuccessful efforts to cut down or control opioid use.
Spending a great deal of time obtaining or using the opioid or recovering from its effects.
Craving, or a strong desire or urge to use opioids
Problems fulfilling obligations at work, school or home.
Continued opioid use despite having recurring social or interpersonal problems.
Giving up or reducing activities because of opioid use.
Using opioids in physically hazardous situations.
Continued opioid use despite ongoing physical or psychological problems likely to have
been caused or worsened by opioids.
10. Tolerance (i.e., need for increased amounts or diminished effect with continued use of the
same amount)
11. Experiencing withdrawal (opioid withdrawal syndrome) or taking opioids (or a closely
related substance) to relieve or avoid withdrawal symptoms.(Dydyk et al., 2021)
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